Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response

Mol Ther. 2016 Feb;24(2):385-397. doi: 10.1038/mt.2015.215. Epub 2015 Dec 15.


A major limiting factor retarding the clinical success of dendritic cell (DC)-based genetic immunizations (DNA vaccination) is the scarcity of biologically safe and effective carrier systems for targeting the antigen-encoded DNA vaccines to DCs under in vivo settings. Herein, we report on a potent, mannose receptor selective in vivo DC-targeting liposomes of a novel cationic amphiphile with mannose-mimicking shikimoyl head-group. Flow cytometric experiments with cells isolated from draining lymph nodes of mice s.c. immunized with lipoplexes of pGFP plasmid (model DNA vaccine) using anti-CD11c antibody-labeled magnetic beads revealed in vivo DC-targeting properties of the presently described liposomal DNA vaccine carrier. Importantly, s.c. immunizations of mice with electrostatic complex of the in vivo DC-targeting liposome and melanoma antigen-encoded DNA vaccine (p-CMV-MART1) induced long-lasting antimelanoma immune response (100 days post melanoma tumor challenge) with remarkable memory response (more than 6 months after the second tumor challenge). The presently described direct in vivo DC-targeting liposomal DNA vaccine carrier is expected to find future exploitations toward designing effective vaccines for various infectious diseases and cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomimetics
  • CD11c Antigen / genetics
  • Cancer Vaccines / administration & dosage*
  • Cancer Vaccines / immunology
  • Dendritic Cells / immunology*
  • Female
  • Immunotherapy, Active
  • Liposomes
  • Mice
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Vaccines, DNA / administration & dosage*
  • Vaccines, DNA / immunology


  • CD11c Antigen
  • Cancer Vaccines
  • Liposomes
  • Vaccines, DNA